[Prostate cancer boost using high-dose-rate brachytherapy: impact of the learning curve on the dosimetry].
Cancer Radiother 2014;
18:659-65. [PMID:
25176296 DOI:
10.1016/j.canrad.2014.04.008]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Revised: 04/13/2014] [Accepted: 04/23/2014] [Indexed: 11/20/2022]
Abstract
PURPOSE
To analyse the influence of the learning curve on dosimetric data for high-dose-rate brachytherapy prostate cancer boost.
PATIENTS AND METHODS
From February 2009 to May 2012, after a first course of external beam radiation therapy (46Gy/23 fractions), 124 patients underwent high-dose-rate brachytherapy boost using Plato™ (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden). The impact of the learning curve on the dosimetric quality of the prostate implant was assessed. The dosimetric data have been analysed: clinical target volume (CTV), D90 (dose to 90 % of CTV), D100, V100 (part on the CTV receiving 100 % of the dose), V150, V200 and DHI (dose non-homogeneity index). The doses delivered to 0.1, 1 and 2 cm(3) of the rectum and urethra were calculated.
RESULTS
During the study period (39 months), a significant reduction of V150 (P<0.001), V200 (P<0.001), D0.1rectum (P<0.001), D1rectum (P<0.001), D2rectum (P<0.001), D0.1urethra (P<0.001), and D1urethra (P<0.002) was observed associated with a significant degradation of the D90 (P<0.001) but not significant for the V100 (P=0.29) and the D100 (P=0.3).
CONCLUSION
This study confirms that the dosimetric quality of high-dose-rate brachytherapy prostate implant is significantly improved during the learning curve period.
Collapse